Pro Medicus (ASX:PME) Jumps 13.04% as Contract Wins and AI Strategy Stay in Focus

Aditi Sarkar

18 August 2026 02:32 PM AEST

Pro Medicus (ASX:PME) Jumps 13.04% as Contract Wins and AI Strategy Stay in Focus

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Pro Medicus (ASX:PME) jumped 13.04% as its contract pipeline and AI strategy remained in focus.
June updates included a five-year AUD 16mn Ohio State University renewal.
The company also signed a five-year AUD 28mn renewal with Allegheny Health Network and a seven-year AUD 16mn TidalHealth contract.
A binding heads of agreement with Echo IQ adds a reseller and financing pathway around AI-enabled cardiac diagnostics.

Pro Medicus (ASX:PME) has jumped 13.04% as the medical-imaging software group continues to build its contracted Revenue pipeline while expanding the role of AI within the Visage ecosystem. June brought multiple contract wins and renewals alongside a heads of agreement with Echo IQ, reinforcing the company’s strategy of combining enterprise imaging software with additional clinical modules.

Contract Renewals Reinforce Recurring Revenue

Pro Medicus announced a five-year AUD 16mn renewal with Ohio State University in June. Earlier in the same month it disclosed a five-year AUD 28mn renewal with Allegheny Health Network and a seven-year AUD 16mn agreement with TidalHealth.

Long-duration contracts remain central to the Visage 7 model because they provide multi-year revenue visibility while expanding the installed base.

Echo IQ Adds an AI Distribution Angle

In late June, Pro Medicus signed a binding heads of agreement with Echo IQ covering a finance Facility and reseller arrangement. The agreement broadens the company’s exposure to AI-enabled cardiac diagnostics without changing its core enterprise-imaging focus.

Half-Year Performance Set a High Base

For the six months to December 2025, Pro Medicus reported revenue of AUD 124.8mn, up 28.4%, and Underlying Profit before tax of AUD 90.7mn, up 29.7%. The company remained debt-free and increased its Interim Dividend to 32 cents per share.

What to Watch

New contract wins, deployment of recently signed agreements, progress under the Echo IQ arrangement and continued Margin performance are the main areas to monitor.

Risks

Pro Medicus trades on expectations of sustained growth. Contract timing, customer concentration, valuation sensitivity, technology competition and execution across new AI products remain relevant risks.

FAQs

Q:What is Pro Medicus’ core platform?

A:The company’s main platform is the Visage 7 enterprise imaging suite.

Q:What recent contract did Ohio State renew?

A:A five-year contract valued at AUD 16mn.

Q:What is the Echo IQ agreement about?

A:It covers a finance facility and reseller arrangement around AI-enabled cardiac diagnostics.

Q:What was HY26 revenue?

A:Revenue was AUD 124.8mn for the six months to December 2025.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.